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Abstract
Background: A high proliferative capacity of tumor cells usually is associated with shortened patient survival.
Disruption of the RB pathway, which is critically involved in regulating the G1 to S cell cycle transition, is a
frequent target of oncogenic events that are thought to contribute to increased proliferation during tumor
progression. Previously, we determined that p18INK4c, an essential gene for normal plasma cell differentiation,
was bi-allelically deleted in five of sixteen multiple myeloma (MM) cell lines. The present study was undertaken to
investigate a possible role of p18INK4c in increased proliferation of myeloma tumors as they progress.
Results: Thirteen of 40 (33%) human myeloma cell lines do not express normal p18INK4c, with bi-allelic deletion
of p18 in twelve, and expression of a mutated p18 fragment in one. Bi-allelic deletion of p18, which appears to be
a late progression event, has a prevalence of about 2% in 261 multiple myeloma (MM) tumors, but the prevalence
is 6 to10% in the 50 tumors with a high expression-based proliferation index. Paradoxically, 24 of 40 (60%) MM
cell lines, and 30 of 50 (60%) MM tumors with a high proliferation index express an increased level of p18 RNA
compared to normal bone marrow plasma cells, whereas this occurs in only five of the 151 (3%) MM tumors with
a low proliferation index. Tumor progression is often accompanied by increased p18 expression and an increased
proliferation index. Retroviral-mediated expression of exogenous p18 results in marked growth inhibition in
three MM cell lines that express little or no endogenous p18, but has no effect in another MM cell line that already
expresses a high level of p18.
Conclusion: Paradoxically, although loss of p18 appears to contribute to increased proliferation of nearly 10%
of MM tumors, most MM cell lines and proliferative MM tumors have increased expression of p18. Apart from a
small fraction of cell lines and tumors that have inactivated the RB1 protein, it is not yet clear how other MM cell
lines and tumors have become insensitive to the anti-proliferative effects of increased p18 expression.
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Background
The RB pathway, which is critically involved in regulating
the G1 to S cell cycle transition, has a central role in the
regulation of proliferation, senescence, and differentia-
tion in most tissues [1,2]. Cyclin D1, D2, or D3 proteins
form complexes with Cyclin D dependent kinases (CDK4
or CDK6), which can then phosphorylate RB-1, and
thereby decrease its ability to inhibit E2F transcription fac-
tors that increase expression of proteins involved in DNA
synthesis. Four INK4 inhibitors (p16INK4a, p15INK4b,
p18INK4c, and p19INK4d) can bind to CDK4 or CDK6,
thereby inhibiting Cyclin D activation of these kinases.
Cell cycle arrest is tightly coupled to terminal differentia-
tion of B cells into plasma cells, a process that is tempo-
rally correlated with an increased expression of p18INK4c
[3,4]. Over-expression of transfected p18 restored coupled
cell cycle arrest and differentiation in a B-lymphoblastoid
cell line that was treated with IL-6. Mice that are null for
p18 developed widespread organomegaly, with an
increased incidence of pituitary tumors [5]. Lymphoid tis-
sues of these mice exhibited increased cellularity, with B
and T lymphocytes showing higher proliferation rates
upon mitogenic stimulation, sometimes manifested as
lymphoproliferative disorders or lymphoma tumors [6].
Significantly, p18 null B cells did not differentiate into
normal plasma cells [7].
One component of the RB pathway is disrupted in most
kinds of tumors, primarily by increased expression of
CDK4, CDK6, or a CYCLIN D protein, or by inactivation
of RB-1 or an INK4 inhibitor (mostly INK4a, or less often
INK4b)[1,2]. It appears that the RB pathway often is dis-
rupted by dysregulation of a Cyclin D gene in multiple
myeloma (MM), a malignant tumor of plasma cells[8,9].
Several years ago, we reported that five of 16 human mye-
loma cell lines (HMCL) have bi-allelic deletion of
p18INK4c[10]. To help elucidate the prevalence, timing,
and significance of p18INK4c abnormalities in multiple
myeloma, we have studied 40 HMCL, 261 MM tumors,
and 16 normal bone marrow plasma cell samples.
Results
Thirteen of 40 human myeloma cell lines do not express 
p18INK4c
Twelve (RPMI-8226; ARP-1; Karpas-620; KMS-12PE; MM-
1; OCI-MY1; OCI-MY5; OCI-MY7; OPM-1; OPM-2;
SKMM-2; XG-6) of 40 HMCL analyzed have no detectable
p18INK4c RNA by an RT.PCR assay (Fig. 1A), and no
detectable p18 exon 3 sequences in genomic DNA (Fig.
1C). The remaining 28 HMCL express p18 RNA at levels
within an approximately twenty-fold range (Table 1).
Western blots (representative results in Fig. 1D) detect an
apparently normal p18 protein at a level that parallels the
level of p18 RNA in 27 of these HMCL, but no p18 protein
was detected in KMS-12BM. Sequence analysis of an
RT.PCR product showed that KMS-12BM had a homoge-
neous p18 sequence, with a TT deletion in codon 21
(CTT) that resulted in conversion of Leu to His, which was
followed immediately by a TGA stop codon. Additional
sequence analyses of RT.PCR products showed no coding
mutations in 13 other HMCL (Table 1).
The consensus minimum deletion region in 13 HMCL 
selectively targets the p18INK4c gene
The p18INK4c gene is located on chromosome band
1p32.3, 9 kb centromeric to the Fas associated factor 1
(FAF1) gene, which encodes a receptor (TNFRSF6) that is
able to mediate apoptosis initiated by interaction with
external FAS ligand (TNFSF6) [11]. Since bi-allelic dele-
tion of p18 might affect FAF1, the minimum deletion
region was determined for each of the 12 HMCL in which
bi-allelic deletion of p18 had been identified (Fig. 2). The
minimum deletion region did not involve FAF1 exons in
three HMCL (KMS12PE; OCI-MY7: MM.1), but included
variable portions of the FAF1 gene in the other nine
HMCL. Consistent with these results, FAF1 RNA was not
expressed in the nine HMCL that had bi-allelic deletions
of some portion of the FAF1 gene. However, with the
exception of a very low level of expression in MM-1, FAF1
RNA was expressed in all other HMCL, including KMS-
12PE and OCI-MY7 (Table 1). Therefore, p18INK4c is the
Table 1: p18 and FAF1 RNA in 39 HMCL
HMCL p18 FAF1 HMCL p18 FAF1
XG-6# 0.01 0.03 XG-1# 1.05 0.97
OPM-1 0.01 0.03 KMS-18 1.22 1.60
8226 0.02 0.04 KMS-28PE 1.24 0.60
KMS12-PE 0.03 1.08 KHM-11 1.29 1.39
OCI-MY5 0.03 0.01 L363 1.41 1.21
MM-1 0.03 0.07 KMS-11 1.45 0.50
SKMM-2 0.03 0.01 U266 1.48 1.28
ARP-1 0.04 0.02 KMM-1 *1.48 1.38
OPM-2 0.04 0.01 JJN-3 1.58 1.16
OCI-MY1 0.05 0.02 KMS-34 1.68 1.08
OCI-MY7 0.06 0.38 ANBL6# *1.75 1.61
FR4 *0.30 1.36 EJM 2.06 1.77
JIM-3 *0.34 0.51 FLAM-76# *2.10 1.66
XG-7# *0.41 1.29 KMS-28BM 2.30 0.56
KMS12-BM **0.53 0.74 LP1 *2.43 1.27
ARK *0.60 1.70 XG-2# 2.46 1.40
MM-S1 *0.72 1.86 PE-1# 2.51 1.36
H1112 *0.80 1.43 H929 *2.91 0.94
SKMM-1 0.97 1.02 UTMC-2 *5.67 1.85
DELTA-47 *1.02 0.89
Normalized RNA content on HG_U133A Gene Chip (see Methods)
# IL-6 added to culture medium
* normal RT.PCR sequence
** mutant RT.PCR sequence (see Results)Cell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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uniform target of deletion, although it is possible that the
associated inactivation of FAF1 could affect the tumor cell
phenotype
We found no evidence for deletion "hotspots" since each
of the twelve HMCL derived from independent tumors
appeared to have unique telomeric and centromeric dele-
tion breakpoint regions (Fig. 2).
The OPM-1 and OPM-2 HMCL, which were derived inde-
pendently from the same tumor specimen [12], had iden-
tical deletion profiles (Fig. 2). Therefore, the deletion
most likely occurred in tumor cells in the patient and not
during generation or propagation of the cell lines.
Bi-allelic deletion of p18INK4c is much less prevalent in 
MM tumors than in HMCL
The expression of p18INK4c RNA was determined for 231
untreated MM tumors, 30 relapsed MM tumors, 33
HMCL, and 16 normal bone marrow plasma cell samples
using Affymetrix HG-U95A Gene Chips. The normalized
expression of p18 RNA for the 310 samples is summarized
in Table 2. Ten of 33 (30%) HMCL have deletion of the
p18 gene and normalized p18 RNA values < 0.55, thereby
defining a maximum background signal. In contrast, only
28 of 261 (11%) MM samples, and none of 16 normal PC
Minimum deletion regions on 1p32.3 for HMCL with bi-allelic deletion of p18INK4c Figure 2
Minimum deletion regions on 1p32.3 for HMCL with bi-allelic deletion of p18INK4c. Pairs of oligonucleotides at the indicated 
positions (relative to the 5' end of the p18 gene) were used in PCR reactions to identify regions of bi-allelic deletion (black if 
not bi-allelically deleted). The positions of the FAF1 (dark gray) and p18 (light gray) genes, and FISH probes are shown.
   Centromeric
15 21 25 28 35 50 63 109 208
X
X
XXXX
X
X
X
X
X
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Telomeric
3' FAF-1 5' 5' p18    3'
 COS tel p18
 COS p18 (42 kb)
  RP11-116M11 (172 kb)
HMCL / kb 543 527 231 104 52 38.8 37.8 8.8 7.2 0 5.9 8.6 14
OCI-MY5
ARP-1 X
8226 X
KARPAS-620 XX
OCI-MY1 X
XG-6 X
SKMM-2 X
OPM-1 XX
OPM-2 XX
MM-1.144 X X
OCI-MY7 X X
KMS-12PE X
KMS-12BM X XX
Expression of p18INK4c in representative myeloma cell lines Figure 1
Expression of p18INK4c in representative myeloma cell lines. 
Results of RNA expression, gene content, and protein 
expression are shown, with experimental details included in 
Materials and Results. Agarose gels show: A) a 521 bp exon2-
exon3 p18 RT.PCR fragment; B) a 248 bp GAPDH RT.PCR 
fragment; and C) a 537 bp p18 exon 3 PCR fragment from 
genomic DNA. Western blots show: D) p18INK4c protein; 
and E) β-tubulin protein.Cell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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samples have p18 RNA values < 0.55. To directly assess
the prevalence of bi-allelic p18 deletion in MM tumors,
we did quantitative real time PCR assays to determine the
content of p18 genomic DNA in 31 MM tumors, includ-
ing twelve tumors with p18 RNA values less than the back-
ground level of 0.55 (representative results in Table 3).
Compared to a reference CYCLIN D3 gene, only three
tumors (P051, P057-2, P303) had a significant decrease
(nine- to fourteen-fold) in p18 gene content compared to
placental DNA. None of the other 28 MM tumors, includ-
ing nine with background values of p18 RNA, had even a
twofold decrease in p18 gene content, so that the expres-
sion array results alone cannot confirm bi-allelic deletion.
Since most purified samples have been estimated to con-
tain greater than 90% tumor cells, it appears that bi-allelic
deletion of p18 occurs in no more than 2 to 3% of MM
tumors compared to about 30% of HMCL.
The prevalence of bi-allelic p18 deletion is higher in more 
proliferative MM tumors
In contrast to highly proliferative HMCL, MM tumors gen-
erally have a low proliferation index [13,14]. To assess
proliferation in MM tumors, we determined an expres-
sion-based proliferation index (PI) from the median
expression of twelve genes that are associated with a pro-
liferation signature (see Methods) [9,15]. A context for the
PI (which includes Ki67, a standard marker to determine
the fraction of cycling cells) is provided by the fact that a
PI>2 occurs in 97% of 33 HMCL, 70% of 30 relapsed MM
tumors, 13% of 231 untreated tumors, and none of 16
normal plasma cell samples (Table 2). As shown in Table
3, all three MM tumor samples (P051, P057-2, and P303)
with bi-allelic deletion of p18 had a PI>2. Only one other
tumor sample (P057), derived from the same patient but
at an earlier time than sample P057-2, had a PI>2; p18
gene content was nearly two-fold decreased in P057, sug-
gesting the possibility that most tumor cells have mono-
allelic deletion of p18, perhaps with some tumor cells
have bi-allelic deletion, and also some contamination by
normal cells. Significantly, none of eight tumors with a PI
<2 and p18 RNA <0.55 had bi-allelic deletion of p18
(Table 3). Including both untreated and relapsed MM
tumors, there were 50 tumors with a PI>2. Six of these
tumors have background levels of p18, and three of the
four tumors analyzed have bi-allelic deletion of p18.
Thus, the prevalence of bi-allelic deletion of p18 in more
proliferative (PI>2) MM tumors is at least 6% but perhaps
10%, a prevalence that still would be lower than the 30%
of HMCL.
HMCL and more proliferative MM tumors frequently over-
express p18
As summarized in Table 2, the normalized expression of
p18 RNA was >2 in twenty of 33 (60%) HMCL, and in 43
of 261 (16%) MM tumors, but in none of 16 normal PC
samples. The increased expression of p18 in MM tumors
was associated with increased proliferation since 5 of
151(3%) MM tumors with a PI<1, 8 of 60 (13%) MM
tumors with a PI between 1 and 2, and 30 of 50 (60%)
MM tumors with a PI>2 had normalized values of p18 >2.
Therefore, unless the p18 gene has been deleted, the
Table 3: p18INK4c content in MM DNA
Sample RNA# ∆∆CT* PI**
P303 0.22 3.8 7.25
P057-2 0.31 3.2 3.10
P051 0.42 3.8 2.82
P301 0.41 0.4 0.57
P063 0.41 -0.8 1.33
P408 0.42 -0.5 0.84
P510 0.46 0.7 0.62
P465 0.46 -0.2 0.46
P057 0.50 0.9 3.48
P222 0.51 -1.4 0.94
P015 0.51 0.8 0.69
P237 0.54 0.0 0.49
P504 0.56 -0.7 0.60
P401 0.58 -0.7 0.48
p102 0.59 -0.8 0.70
P266 0.87 0.3 0.46
P277 0.88 0.2 0.82
P208 1.08 0.0 0.91
P067-1 1.17 0.3 0.51
P175 1.34 -0.2 0.80
P250 1.41 0.6 0.73
P163 1.49 -0.5 0.92
# Normalized RNA content by HG_U95A analysis
* real time PCR for p18 DNA content
** expression-based proliferation index
See Materials and Results for details.
Table 2: p18 RNA and expression-based proliferation index (PI)
normalized p18 RNA*
# PC ≤0.55 0.55–1 1–2 >2
PI<1 1 6 021 4 0
# HMCL
PI<1 0 0000
PI 1–2 1 0001
PI >2 32 10 0 3 19
Total HMCL 33 10 0 3 20
# MM
PI<1 151 19 89 38 #5
PI 1–2 6 0 3 3 21 78
PI >2 50 #6 4 10 #30
Total MM 261 28 125 65 43
* Summary of HG_U95A RNA expression data (Methods and Results 
for details)
# P < 0.00001Cell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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expression of p18 RNA usually is increased in HMCL and
more proliferative MM tumors.
A proliferation signature is associated with a poor progno-
sis in many kinds of tumors, including MM tumors
[15,16]. Figure 3 shows a survival curve of 596 individuals
with MM tumors, including 559 individuals with
untreated tumors and 37 individuals with relapsed
tumors[16]. There is a significantly reduced overall time
of survival for individuals whose tumors have an expres-
sion based proliferation index greater than two (P <
0.0001). Given the strong correlation of a PI>2 with
increased expression of p18INK4c, it is not surprising that
the overall survival time of individuals with tumors hav-
ing a normalized expression of p18>2 is also significantly
reduced (P = 0.0005). In fact, we confirmed that PI is
more important than p18 in determining survival since
PI>2 with p18<2 also is associated with a significantly
poorer prognosis, whereas p18>2 with PI<2 is not associ-
ated with a significantly poorer prognosis.
Transfected p18 inhibits proliferation of some but not all 
HMCL
To assess the effect of exogenous p18 on proliferation of
HMCL that express different amounts of endogenous p18,
we used a retroviral vector that co-expresses p18 from the
5' LTR and a puromycin-EGFP fusion product from an
internal CMV promoter[17]. We retrofected four HMCL:
KMS-12PE and OPM-2 have bi-allelic deletion of p18;
JIM-3 expresses a low level of p18; and L363 expresses a
high level of p18 (Table 1). Representative results from
these experiments are shown in Figure 4. As assessed from
Western blots, the level of expression of exogenous p18 in
unselected OPM-2 (15% EGFP positive cells) indicated
that infected cells express exogenous p18 at a level that is
comparable to the endogenous level of p18 in L363 (Fig.
4A). The level of endogenous plus exogenous p18 in puro-
mycin selected (EGFP+) L363 cells appears to be almost
twofold higher than the level of endogenous p18 in L363
(Fig. 4A and other results not shown).
To determine the effect of exogenous p18 on growth, the
percentage of EGFP positive cells – for both the control
and p18 vectors – was determined the day after infection
(0 cell doublings), and at two additional times as the
entire cell population went through a total of five dou-
blings in the absence of puromycin selection (Fig. 4B). For
all HMCL retrofected with the control vector, the fraction
Retrofection of p18 into four HMCL Figure 4
Retrofection of p18 into four HMCL. Representative results 
are shown for retrofection of four HMCL with pVPG-0 or 
pVPG-p18 vector. A. Western blot containing extracts from 
uninfected or infected HMCL. Dilutions of L363 are shown 
to compare endogenous p18 expression with transfected 
cells: 1)100 µg uninfected OPM-2; 2)100 µg OPM-2.p18(15% 
EGFP+); 3)12.5 µg L363; 4)25 µg L363; 5)12.5 µg L363.p18 
(puromycin selected); 6) 100 µg of JIM-3. B. Relative growth 
of infected cells that express EGFP after infection with 
pVPG-0 (only L363 is shown) or pVPG-p18 (all four HMCL), 
starting one day after infection (0 generations). The ordinate 
is the fraction of EGFP cells (normalized to the % EGFP posi-
tive cells one day after infection) and the abcissa is the 
number of generations of the total cell population. Symbols: 
diamond, L363 (pVPG-0); box, L363; horizontal line, JIM-3; 
triangle, OPM-2; open circle, KMS-12PE.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
012345
Generations
Fraction
EGFP +
cells
23 4 5 6 1
A
B
Effect of increased proliferation or increased p18INK4c  expression on survival of multiple myeloma patients Figure 3
Effect of increased proliferation or increased p18INK4c 
expression on survival of multiple myeloma patients. Survival 
data and Affymetrix U133_2.0_Plus RNA expression data 
was obtained for 596 individuals with MM, including 559 
newly diagnosed patients and 37 patients in relapse. Kaplan-
Meier curves of overall survival are shown. Compared to the 
total population, 101 patients with an expression- based pro-
liferation index (PI) >2 had a significantly shorter survival (P < 
0.0001), and 107 patients with a normalized p18INK4c 
expression > 2 also had a significantly shorter survival (P = 
0.0005).
0 12 24 36 48 60 72
0
50
100  ALL (596)
 p18 >2 (107)
 PI >2 (101)
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of EGFP positive cells increased somewhat during the first
two doublings but then remained essentially stable
(shown only for L363 in Fig. 4B); this transient period of
a relative increase of transfected cells probably is
explained by the fact that retroviruses efficiently infect the
most healthy, proliferating cells. The growth properties of
L363 cells infected with the p18 and control vectors were
indistinguishable, indicating no effect of exogenous p18
on cell growth. However, for the other three HMCL that
were infected with the p18 vector, the fraction of EGFP
positive cells continuously decreased as the population
underwent five doublings (Fig 4B). Assuming comparable
viability for the transfected and non-transfected cells in
each population, we have calculated (Methods) the
approximate fractional growth inhibition by exogenous
p18 for each of these three HMCL: 79% in a single exper-
iment with OPM-2; 61 and 69% in two experiments with
KMS-12PE; 52 and 54% in two experiments with JIM-3.
For L363 and OPM-2, we also did a FACS analysis to
determine the DNA content as a measure of cell cycle dis-
tribution of EGFP positive cells. For L363 cells examined
two population doublings after infection, the fraction of
EGFP positive cells with G0/G1 and S DNA content,
respectively, was 0.42 and 0.36 with the control vector,
and 0.44 and 0.31 with the p18 vector. In marked con-
trast, for OPM-2 cells examined two population dou-
blings after infection, the fraction of EGFP positive cells
with G0/G1 and S DNA content, respectively, was 0.42
and 0.35 with the control vector, but 0.85 and 0.05 with
the p18 vector. Therefore, unlike the high p18 expressing
L363 where exogenous p18 had no inhibitory effect, the
cell cycle and proliferation analyses of p18 null OPM-2
cells are consistent with exogenous p18 markedly inhibit-
ing progression from G1 to the S phase of the cell cycle,
thereby causing a substantial inhibition of cell prolifera-
tion.
Discussion
What are the roles of the INK4a, INK4b, and INK4d genes 
in MM?
Although polymorphic germline alleles and/or somatic
loss of INK4a expression are critical oncogenic factors in
murine plasmacytoma tumors [18], the situation is less
clear in MM. One individual from a melanoma prone
family that carried a germline mutant INK4a gene devel-
oped MM, and his tumor cells showed selective loss of the
normal INK4a allele [19]. There are no other reports of
mutations affecting any of the INK4 genes, but MM
tumors with bi-allelic deletion of INK4a, INK4b, and
INK4c have been reported [20]. There is scant information
about the expression of any of the INK4 genes in MM [21-
23]. However, several groups have reported that the
INK4a promoter is methylated in 20 to 55% of MM
tumors, and more than 80% of extramedullary MM
tumors and HMCL [21,24-29]. Some of these same stud-
ies also showed a substantial but variable fraction of
tumors with methylation of the p15INK4b promoter. The
most rigorous study reported that there is methylation of
the INK4a promoter in about 20% of purified pre-malig-
nant MGUS (monoclonal gammopathy of undetermined
significance) or MM tumor cells, and the INK4b promoter
in about 30% of purified MGUS or MM cells [25]. Signif-
icantly, a very recent study shows that methylation of p16
occurs at a similar prevalence in MGUS and MM, has no
significant effect on expression of p16 RNA, and has no
prognostic significance [30]. We also have found little or
no expression of p16INK4a RNA in most MM tumors and
cell lines, even in the absence of promoter methylation (A.
Dib and M. Kuehl, unpublished). Thus it appears that
inactivation of p16 expression may not be an oncogenic
event in MM, and that p16 methylation may be an epi-
phenomenon associated with disease progression. There
is virtually no information about the status of INK4d in
MM. Although INK4a and INK4b may not be expressed in
many (perhaps most) MGUS and MM tumors, presently
there is no convincing evidence for oncogenic roles of
INK4a, INK4b, or INK4d inactivation in MGUS or MM
tumors.
Why is bi-allelic deletion of p18INK4c more prevalent in 
HMCL than in MM tumors?
Two possibilities need to be considered in accounting for
our finding that nearly one third of HMCL have bi-allelic
deletion of p18INK4c, whereas the prevalence is less than
10% for MM tumors that have a comparably high PI. First,
since HMCL are preferentially derived from non-hyper-
diploid tumors that have a higher prevalence of IgH trans-
locations and other chromosomal structural
abnormalities than hyperdiploid tumors[8,14,31], it is
possible that these tumors are more likely to have intersti-
tial deletions that involve p18. Second, there might be a
stronger selection for bi-allelic deletion of p18 for extra-
medullary tumors (and thus HMCL since virtually all of
these lines are derived from extra-medullary tumors) com-
pared to intramedullary tumors. In this regard, it is nota-
ble that KMS-12BM and KMS-12PE, which were derived at
different times from the same patient [32], utilized inde-
pendent events to fully inactivate p18.
When does bi-allelic deletion of p18 occur?
It seems likely to be a late progression event since it is
more prevalent in MM tumors that have a high prolifera-
tion index, which typically occurs late in tumor progres-
sion [13,14,33]. More significantly, sequential samples
from the same patient showed that only the later sample
(P057-2) had bi-allelic deletion of p18 (Results and Table
3).Cell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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Does bi-allelic inactivation of p18 enable increased 
proliferation?
We do not know if bi-allelic deletion or inactivation of
p18 is sufficient for increased proliferation of MM tumors.
However, the retroviral mediated expression of p18 in two
HMCL (KMS12-PE and OPM-2) that do not express
endogenous p18, and in a third HMCL (JIM-3) that
expresses very low levels of p18 results in a substantial
inhibition of proliferation. Thus, it seems clear that inac-
tivation or decreased expression of p18 represents an
important mechanism that contributes to increased pro-
liferation of some MM tumors.
Disruption of the RB pathway can involve at least two 
independent events in the same MM tumor
It has been shown that IgH translocations, which are
thought to represent very early – if not initiating – events
in the pathogenesis of MGUS and MM, directly dysregu-
late CYCLIN D1 or CYCLIN D3 in about 20% of tumors,
and indirectly dysregulate CYCLIN D2 in another 10% or
so of tumors [8,17,33]. Dysregulation of one of the CYC-
LIN D genes may, in fact, represent a virtually universal
early event in the pathogenesis of MGUS and MM[8,9].
The low proliferative capacity of MGUS or MM tumors
that express a dysregulated CYCLIN D gene is consistent
with transgenic models. The high level of expression of
transgenic CYCLIN D1 in murine B cells does not seem to
perturb normal B cell development and proliferation or
lead to tumors unless there is a cooperating oncogenic
transgene, such as MYC or activated RAS [34,35]. The bi-
allelic inactivation of p18 in HMCL is neither negatively
nor positively correlated with the presence of an IgH
translocation that directly dysregulates CYCLIN D1, or a
MAF gene that indirectly dysregulates CYCLIN D2.
Although initially it was thought that only one compo-
nent of the RB pathway is disrupted in tumors [1], it
increasingly is apparent that this is not uniformly true[2].
In addition to examples of tumors in which two different
INK4 genes are inactivated, it recently was reported that
mantle cell lymphoma, most of which have an IgH trans-
location that dysregulates CYCLIN D1, become more pro-
liferative when the INK4a/ARF locus is deleted[15]. Thus
it appears that for both MM and mantle cell lymphoma,
dysregulation of a CYCLIN D gene is an early event asso-
ciated with low proliferation, whereas inactivation of an
INK4 gene can be a late event associated with increased
proliferation and a poorer prognosis.
Why do most HMCL and highly proliferative MM tumors 
express increased levels of p18?
Compared to normal plasma cells, the level of p18 expres-
sion is increased in most HMCL that have not bi-alleli-
cally deleted p18 (Table 2 and Results). This increased
expression also occurs in 60% of MM tumors that have a
PI>2 (comparable to HMCL), whereas MM tumors with a
PI <1 rarely have increased expression of p18. Direct sup-
port for the conclusion that p18 increases during disease
progression has come from expression studies on paired
samples taken from patients prior to the initiation of ther-
apy and at relapse. In 22 of 51 (42%) cases, p18 increased
an average of 7 fold, and this was associated with an
increase in PI (P < 0.0001) (FZ and JS, unpublished). It
has been shown that the p18 promoter region has a
number of E2F and SP1 binding sites, and that the expres-
sion of p18 RNA and protein is up-regulated by E2F1 and
SP1 transcription factors [36]. Increased proliferation,
which is associated with increased activity of these tran-
scription factors, would be expected to cause increased
expression of p18. However, a high level of proliferation
with a corresponding high level of p18 suggests that the
RB pathway has become insensitive to the inhibitory
effect of p18 on CDK-Cyclin D mediated phosphorylation
of RB-1. The lack of a growth inhibitory effect of increased
p18 expression in retrofected L363 cells (Fig. 4B) supports
this inference. The apparent insensitivity of most HMCL
to the inhibitory effects of INK4 inhibitors is consistent
with the observation that there is a high level of p16INK4a
RNA expression in three HMCL (EJM, Flam-76, PE-1) that
also express high levels of p18 (Table 1) but not in HMCL
that have bi-allelic deletions of p18; whereas 37 of 40
HMCL express little or no p16 RNA (A. Dib, unpub-
lished). The increased expression of p18 in proliferative
MM cells is reminiscent of the increased expression of
p16INK4a in small cell lung cancer tumors that have inac-
tivated the RB-1 gene[37]. In fact, although we have found
that RB-1 protein is expressed in most of the 40 HMCL we
have examined, it is not expressed in four HMCL (KMS-
18, KMS-28BM, KMS-28PE, U266), providing an explana-
tion for insensitivity to the expression of high levels of
p18 in these cell lines (A. Zingone, unpublished)[38].
Others have shown that RB-1 protein is not expressed in
about 5% of a limited number of MM tumors that have
been analyzed[39,40]. Thus, inactivation of RB-1 appar-
ently accounts for only a small fraction of HMCL or pro-
liferative MM tumors that express increased levels of p18.
Recently, it was suggested that increased proliferation of
MM tumors is due to increased expression of CDK4 and/
or CKD6 [41]. However, there was only a minimum of
data supporting this hypothesis, and we could not dem-
onstrate a significant correlation of increased CDK4 or
CDK6 RNA expression with an increased expression based
proliferation index in primary MM tumors. Finally, in
comparing the gene expression profiles of HMCL that
express high levels of p18 vs HMCL that have bi-allelic
deletion of p18, we do not observe significant differences
in gene expression for these two groups (data not shown).
Conclusion
It seems apparent that increased proliferation of MM
tumors sometimes is related to inactivation or decreasedCell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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expression of p18INK4c. However, apart from a small
fraction of tumors that inactivate RB-1, it remains to be
determined how most MM tumors are able to overcome
the anti-proliferative effect of a high level of p18INK4c.
Methods
Cell culture
The 40 HMCL in this study included Karpas-620 and the
39 HMCL in Table 1. [42].
PCR analyses
Procedures for isolation of total RNA and DNA, synthesis
of cDNA, PCR reactions, gel electrophoresis, and isolation
of fragments for sequencing were described previously
[42]. The expression of p18 RNA (reference sequence
NM001262) was determined using a cDNA template with
nt 1204–1224 (exon 2) and nt 1722-1698 (exon 3) as
primers. To determine the sequence of the p18 coding
region (nt 1216–1722), nt 1164–1185 and nt 1784-1765
were used as primers. Exon 3 of p18 was amplified from
genomic DNA using nt 1477–1498 and nt 2011-1991 as
primers.
p18 Western blotting
Total protein lysates (50 µg) were resolved by electro-
phoresis on 12% polyacrylamide/SDS gels, and trans-
ferred to nitrocellulose membranes. Antibody SC-865
(Santa Cruz Biotechnology) was used to detect p18, and
AA2 antibody (Upstate) was used to detect β-tubulin [42].
p18INK4c deletion map
A sequence contig that included the p18INK4c gene was
obtained from NCBI. After exclusion of repetitive
sequences, PCR primer pairs encompassing the p18 gene
and 750 kb of flanking sequences were designed and val-
idated using a placental DNA template.
Real-Time quantitative PCR on genomic DNA
These analyses were performed using the ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA). Primers-probe sets (Synthegen, Houston, TX)
included: AGGGCCACCGAACTGCTACT, GTGGCT-
GGATGCTGACGTG, and (FAM)CGCCTTTGGCGAT-
CATCTTTTAACCCT(TAMRA) for p18INK4c; and
TCACAAAGCCCAAGGGATCT, AAAGGCGCTGCTGGT-
CAG, and (JOE)CCGGCCAGCCATGTCTGCATT(TAMRA)
for CYCLIN D3. Multiplex PCR reactions were carried out
with the TaqMan Universal PCR Master Mix, AmpErase
UNG (Applied Biosystems, Branchburg, NJ, USA). The
PCR conditions were as described by the manufacturer.
Triplicate or quadruplicate experiments were done for
each sample, and the threshold cycle values were averaged
using the Sequence Detector software 1.7 (Applied Biosys-
tems). For each sample, the average Ct value for the
endogenous CYCLIN D3 reference was subtracted from
the average Ct value for p18, to yield the ∆Ct. The placen-
tal DNA ∆Ct was subtracted from the ∆Ct for each sample
to give the corresponding ∆∆Ct for each sample.
Affymetrix gene expression analyses
Isolation of purified normal or tumor plasma cells, and
profiling of RNA was performed as described previously
[43,44]. Gene-expression intensity values, which were
obtained with the use of Affymetrix version 5.01 MAS
software, were log transformed and normalized to the
median of all genes for each sample, and analyzed using
GeneSpring 5.1 (Silicon Genetics, Redwood City, CA).
The expression of a specific gene was normalized to the
median expression of that gene in the 40 HMCL analyzed
on HG-U133 Set Affymetrix Gene Chips, in the 310 sam-
ples analyzed on HG-U95A Affymetrix Gene Chips, or in
the 596 tumors analyzed on HG-133-2.0-Plus chips. The
average of the normalized values for two p18INK4c
(204159_at; 211792_s_at) or three FAF1 (218080_x_at;
222511_x_at; 224217_s_at) U133 probe sets is shown in
Table 1. The RNA from 10 HMCL and 10 primary MM
tumors that cover the full range of p18 expression were
analyzed by RT.PCR assays (Applied Biosystems, Foster
City, CA) to validate the HG-U95A and HG-U133 quanti-
tation of p18 RNA content. For the U95A data set (Tables
2 &3), an expression-based proliferation index (PI) was
calculated using the median value of twelve genes associ-
ated with a proliferation signature (9, 15). For 596 tumors
analyzed on Affymetrix HG_U133_2.0_Plus Gene Chips,
the 12 probe sets used to calculate a PI included:
214710_s_at; 212022_s_at; 202503_s_at; 206102_at;
201897_s_at; 201292_at; 202954_at; 204026_s_at;
204033_at; 204444_at; 203418_at; 202870_s_at. The
proliferation index, calculated from the median expres-
sion of these twelve genes, was strongly correlated with
expression of each gene (R > 0.85 for each gene).
p18 retrofection[17]
Normal p18 cDNA encompassing 4 bases upstream of the
ATG and 12 bases downstream of the termination codon
(nt 1212–1736) was PCR amplified from EJM cDNA,
cloned into BamHI and XhoI sites to generate pVPG-p18,
and the coding sequence verified by sequencing. For both
the p18 and control vector, infection efficiencies, esti-
mated from the fraction of EGFP positive cells one day
after infection, were approximately 15 to 20% for each of
the HMCL except JIM-3, which was 6 to10%. Assuming
equal viability of EGFP positive (transfected) and EGFP
negative cells without puromycin selection, a decreased
fraction of EGFP positive cells with successive population
doublings provides a measure of fractional growth inhibi-
tion (i), using the equation: n log [(2 - i)/2] = log (%EGFP
cells after n population doublings/%EGFP cells initially).Cell Division 2006, 1:23 http://www.celldiv.com/content/1/1/23
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Flow cytometry
The fraction of EGFP positive cells was determined with a
FACSort (BD Biosciences). For cell cycle analysis, cells
were stained with Hoechst 33342 at a concentration of 5
µg/ml for 90 minutes at 37°C. An LSR II BD (BD Bio-
sciences) and FACSDiVa software was used to determine
the DNA content of individual cells, including EGFP pos-
itive and negative cell populations[45]. The fractions of
cells in G0/G1, S, and G2/M were calculated using ModFit
software (Becton Dickinson).
Survival data
Survival data and RNA expression data for purified MM
tumor cells analyzed on HG_U133_2.0_Plus Gene chips
was obtained on 596 patient with MM, including 549
patients with newly diagnosed MM and 37 patients with
relapsed MM, as described in detail elsewhere[16].
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